FindTrial
Sign In

Frequency: twice daily

5 trials

Sponsors

Intas Pharmaceuticals Ltd, Prinston Pharmaceutical Inc, Intas Pharmaceuticals Limited

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 1: F209- Schizophrenia, unspecifiedHealth Condition 1: H104- Chronic conjunctivitisHealth Condition 1: L649- Androgenic alopecia, unspecified

Phase 2

A study of tacrolimus lipid suspension in adult patients of allergic conjunctivitis
Active, not recruitingCTRI/2021/05/033314
Intas Pharmaceuticals LtdHealth Condition 1: H104- Chronic conjunctivitis
Target: 36Updated: 2023-01-09

Phase 4

A study for Evaluation of effectiveness and Safety of Minoxidil (5%) plus Finasteride (0.1%) Solution in Adult Male Patients with Androgenetic Alopecia
Active, not recruitingCTRI/2016/03/006724
Intas Pharmaceuticals LtdHealth Condition 1: L649- Androgenic alopecia, unspecified
Target: 160Updated: 2021-11-24

Unknown Phase

A bioequivalence study of clozapine tablet 100 mg twice daily (test drug) with Clozaril® 100 mg tablets twice daily (reference drug, Novartis pharmaceuticals corporation, USA) in adult schizophrenic patients under fasting conditions.
Active, not recruitingCTRI/2016/07/007065
Prinston Pharmaceutical IncHealth Condition 1: F209- Schizophrenia, unspecified
Target: 38Updated: 2021-11-24
A comparative study of Capecitabine Capsules 500 mg and Capecitabine tablet 500 mg in patients of breast, colon or rectal cancer
Active, not recruitingCTRI/2018/01/011492
Intas Pharmaceuticals LimitedHealth Condition 1: C509- Malignant neoplasm of breast of unspecified site
Target: 24Updated: 2021-11-24
A Study of Clozapine Extended Release Capsule 200 mg with Clozaril® 100 mg Tablets in Adult Schizophrenic Patients.
Active, not recruitingCTRI/2019/12/022239
Intas Pharmaceuticals LimitedHealth Condition 1: F209- Schizophrenia, unspecified
Target: 136Updated: 2021-11-24